![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F1.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F3.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/sites/default/files/highwire/jneuro/31/19.cover-source.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![Box of Quetiapine tablets, an atypical antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder Stock Photo - Alamy Box of Quetiapine tablets, an atypical antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder Stock Photo - Alamy](https://c8.alamy.com/comp/2AJBAGE/box-of-quetiapine-tablets-an-atypical-antipsychotic-drug-used-for-the-treatment-of-schizophrenia-bipolar-disorder-and-major-depressive-disorder-2AJBAGE.jpg)
Box of Quetiapine tablets, an atypical antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder Stock Photo - Alamy
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F4.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F2.large.jpg)